Dermatoses induced by multikinase inhibitors: A case report

Abstract

Multikinase inhibitors, such as sorafenib and lenvatinib, are used in the treatment of patients with renal and hepatocellular carcinoma. Their mechanism of action includes the inhibition of neoangiogenesis through VEGFR, KIT, PDGF, RET, and fibroblast growth factor receptors. A sixty-year-old patient of Indian origin presented to our dermatology OPD with a history of HCC under treatment with sorafenib and a twelve-month history of progressive, pruritic, erythematous, papulosquamous rash on the lower extremities, lumbosacral region, anterior abdomen, perianal region, and perineum. On examination, the patient had tender, desquamative lesions on the palms and soles. He had developed a bullous eruption on the lateral side of both feet and the dorsum of the ankle joint and foot. He was under treatment with sorafenib for twelve months and switched to lenvatinib for two months. ADRs require early diagnosis and effective management in order to make sure that lifesaving anti-neoplastic therapy may be continued uninterrupted. Key words: Lenvatinib; Sorafenib; Multikinase inhibitors; HCC; Cutaneous reactions